Let's Get Started

Business

Limitless Venture Group LVGI Bullish?

Limitless Venture Group LVGI Bullish?

Jan 11, 2022

Limitless Venture Group LVGI is up 98% after due to a massive amount of volume being injected into this little well known stock that has been crashing for the last 6 months. I have written a full report on LVGI that you can read below.

However, before you read this insightful information, sign up below, let’s stay in contact.

LVGI

Limitless Venture Group announced today, “the best revenue year in the history of LVGI and update shareholders on what’s ahead for 2022 and beyond.” However, before we get started, let’s review some basic information on this company.

Limitless Venture Group LVGI Company Summary

Company Name:  Limitless Venture Group, Inc

Ticker: LVGI

Exchange: OTC

Website: www.lvginc.com

Limitless Venture Group, Inc. Company Summary

Limitless Venture Group provides its shareholders with access to leading small and medium-sized businesses focused on growth. Leveraging its permanent capital base, disciplined long-term approach, and actionable expertise, LVGI owns controlling interests in its subsidiaries as it partners with management teams to build businesses with the capacity to unlock significant value for its shareholders.

The Company currently has three primary subsidiaries: Rokin, Inc., KetoSports, Inc. and Jasper Benefit Solutions, LLC.

Also, Rokin was founded in 2016 with a mission to provide our customers with the highest quality, technology-driven vaping products available while providing exceptional customer service.

Moreover, KetoSports products flush the body with ketones, raising blood ketone levels within a few minutes.

Also, Jasper Benefit Solutions, LLC (JBS), founded in 2018 with headquarters just outside Nashville, TN, is a Managing General Underwriter (MGU) specializing in risk management services for small to medium self-funded employer “Groups”. 

Consequently, Rokin, KetoSports & Jasper Benefit Solutions have benefitted greatly from the management expertise at LVG.

LVGI News

January 11 , 2022

Announced the best revenue year in the history of LVGI and update shareholders on what’s ahead for 2022 and beyond. HERE

December 7, 2021

Announced that it has signed an LOI to acquire 100% of an Oklahoma operating grow facility with both Indoor and outdoor operations, exclusive to LVGI for 60 days from the signing of the LOI. HERE

Limitless 1 Month Chart

LVGI

LVGI 1 Day Chart

LVGI

Limitless Venture Group Technical Analysis

The news was incredible that Limitless Venture Group LVGI released today was huge and the stock responded with a massive amount of volume and a PPS increase of 251%. LVGI skyrocketed from $.011 to $.0388 with 50 million+ shares traded.

The real question is, what is it going to do now? Well, it has pulled back as expected but it will now consolidate. Next, it will make a move up or down depending on the indicators within the consolidation. It is too early to determine which way it will move, but it is showing an early tendency to bearish.

I would expect The news was incredible that Limitless Venture Group LVGI released today was huge. The stock responded with a massive amount of volume and a PPS increase of 251%. LVGI skyrocketed from $.011 to $.0388 with 50 million+ shares traded.

I would expect, the news was incredible that Limitless Venture Group LVGI released today was huge and the stock responded. Therefore, LVGI opened with a massive amount of volume and a PPS increase of 251%. LVGI skyrocketed from $.011 to $.0388 with 50 million+ shares traded.

I am thinking Limitless will continue to drop in PPS until it fully consolidates then it will make a run! Stay tuned traders

Remember, to never try and catch a falling safe, or a knife for that matter. Simply let it fall to the ground, walk over, and pick up the money and walk away. If you enjoyed this article, sign up below, I promise I will never spam you and I’m pretty darn good at picking winners. Let’s make some trades together!

LVGI

read more
Freeline Therapeutics FRLN report

Freeline Therapeutics FRLN report

Jan 6, 2022

Freeline Therapeutics Holdings plc (FRLN) is going down down down but is the there a reversal coming soon?

Freeline Therapeutics FRLN Company Summary

Company Name: Freeline Therapeutics Holdings plc

Ticker: FRLN

Exchange: NASDAQ

Website: https://www.freeline.life/

Freeline Therapeutics FRLN Company Summary

Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases.

Freeline uses its proprietary, rationally designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into the patient’s bloodstream.

The Company’s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing, and commercialization. The Company has clinical programs in hemophilia B, Fabry disease, and Gaucher disease Type 1. Freeline is headquartered in the UK and has operations in Germany and the US.

Freeline Therapeutics FRLN News

Jan. 06, 2022

Announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for FLT201 as an investigational gene therapy for the treatment of Gaucher disease Type 1.

“The FDA clearance of this IND is an important milestone for FLT201, which is the first AAV-mediated gene therapy for patients with Gaucher disease Type 1 in the clinic,” said Michael Parini, Chief Executive Officer of Freeline. “Our FLT201 program harnesses our unique scientific platform capabilities – our highly potent, proprietary AAVS3 capsid, robust CMC and pre-clinical data across all our programs, and our advanced protein engineering capabilities – to develop a potentially transformative treatment for patients suffering from Gaucher disease. The entry of our third program into the clinic is important validation of the advantage of Freeline’s portfolio approach to development.”

Freeline Therapeutics FRLN Stock Chart

FRLN Analysis

There is resistance at $2.10 and $2.15 and this stock will continue to go down unless it can correct and breakout of the two resistance points. The news is great, so I expect a consolidation soon and a correction. Make sure to keep this on your radar.

read more
Kaival Brands KAVL ready to breakout?

Kaival Brands KAVL ready to breakout?

Jan 6, 2022

Kaival Brands KAVL has been in a bearish trend and it is possible that there has been a reversal. Take a look at this chart.

Kaival Brands KAVL Company Summary

Company Name: Kaival Brands Innovations Group, Inc.

Ticker: KAVL

Exchange: NASDAQ

Website: www.ir.kaivalbrands.com.

Kaival Brands Company Summary:

Based in Grant, Florida, Kaival Brands is a company focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets.

Our vision is to develop internally, acquire, own, or exclusively distribute these innovative products and grow each into dominant market-share brands with superior quality and recognizable innovation. Kaival Brands is the exclusive global distributor of all products manufactured by Bidi Vapor.

KAVL News

Dec. 14, 2021 

Announced today that 80% of adult participants in a recent survey of e-cigarette users and cigarette smokers in the United Kingdom (“U.K.”) preferred the BIDI® Stick over their current options.

Dec. 6, 2021

Announced that it has partnered with Koupon to create an electronic engagement program involving Koupon’s digital promotion platform. The partnership will offer customers who purchase the BIDI® Stick—a premium electronic cigarette—digital opportunities based on their purchases.

KAVL 1 Day Chart

Kaival Brands Innovations Group, Inc. (KAVL) analysis

This stock is trying it’s best to break the second level of resistance and it should move once it does. Keep an eye on the $.78 PPS, it is a resistance point that is important!

read more
China Tower (CHWRF) Update

China Tower (CHWRF) Update

Jan 5, 2022

China Tower Corporation Limited is possibly about to breakout.

Company Name:  China Tower Corporation Limited

Ticker: CHWRF

Exchange: OTC

Company Summary:

is a China-based telecommunications tower infrastructure service provider. The Company mainly has three business segments.

China Tower 5 Day Chart

China Tower Corporation 1 Day Chart

China Tower Corporation Limited (CHWRF) technical analysis

China Tower Corporation Limited (CHWRF) is up 10% and has broken out of its low. Keep a careful eye on this one because of the low volume it will be a tough one to get out of cause it is thinly traded.

read more
ShiftPixy PIXY up huge

ShiftPixy PIXY up huge

Dec 29, 2021

ShiftPixy PIXY up huge after heavy volume after the last few days. The stock skyrocketed up over 100% in two trading days. The stock is currently consolidating and deciding what it wants to do next.

Let’s take a quick look at ShiftyPixy

Company Name: ShiftPixy, Inc. 

Ticker: (PIXY)

Exchange: NASDAQ

Company Summary:

ShiftPixy is inching closer to its goal of becoming a national staffing leader after raising $115 million in an initial public offering for Industrial Human Capital, a blank check company formed to acquire industrial staffing companies.

Industrial Human Capital is one of four special purpose acquisition companies (SPACs) formed by ShiftPixy, a Miami-based platform that connects businesses with short-term hires and gig workers.

Why did it go up over 100%?

No big news, just this. I don’t think that warrants the incredible increase in share price.

ShiftPixy PIXY) 1 Day Chart

ShiftPixy PIXY Technical Analysis:

It has been consolidating the whole day after a morning rush of volume driving the PPS up almost 50% with high volume. The stock seems very stable in the consolidation pattern. I would wait till PIXY breaks above $1.68 or at least $1.64 before considering a purchase. 

I would place my stop loss at $1.45, because, if it goes below, it will pull back. The stock is very interesting with relatively no news and feels like an awareness campaign but the stock is stable. Wait for confirmation at $1.64 before moving on it and make sure to keep an eye on it.

read more
Reliance Global Group RELI is very bullish

Reliance Global Group RELI is very bullish

Dec 29, 2021

Let’s take a quick bird’s eye view of Reliance Global Group RELI and why RELI is up over 200% in less than two weeks. Before we get started, let’s go over the particulars.

Company Name: Reliance Global Group

Ticker: RELI

Exchange: NASDAQWebsite: https://www.relianceglobalgroup.com/

Reliance Global Group Company Summary:

Reliance Global Group, Inc. (NASDAQ: RELI, RELIW) is combining advanced technologies, with the personalized experience of a traditional insurance agency model.

Also, Reliance Global Group’s growth strategy includes both an organic expansion as well as acquiring well managed, undervalued and cash flow positive insurance agencies.

Why did it go up over 200%?

Reliance Global Group RELI announced a private placement of preferred stock, common stock and warrants for gross proceeds of $20.0 million before deducting the placement agent’s fees and other estimated offering expenses.

The offering is expected to close on or around December 27, 2021.

Reliance Global Group RELI 1 Day Chart:

RELI technical analysis

I expect it to consolidate in between $6.13 & $6.36 before the next move. I’m feeling good about this stock and believe with the big news and the overall bullish trend in the 5 day and 1 day that it is a stock to watch carefully! 

If the stock falls below $6.13, that is an indicator of a pullback so be careful!

read more
Dais Corp DLYT up over 2,000%

Dais Corp DLYT up over 2,000%

Dec 21, 2021

Company Name: Dais Corporation 

Ticker: (DLYT)

Exchange: OTC

Website: https://daisanalytic.com/

Company Summary:

Dais Corporation is a nanotechnology business producing a versatile platform of nanotechnology membrane materials (called Aqualyte™) addressing evolutionary and disruptive air, energy, and water applications. These proven products are characterized by offering Climate Change emission and energy reductions, longer lifetimes, and competitive pricing in the HVAC, Water, and Energy industries. Current commercial revenues come from selling:

  • Advanced Aqualyte™ nanomaterials to a wide range of OEMs wishing to create new or highly differentiated products which embrace the moisture management features of the product.
  • ConsERV™, a commercially available HVAC engineered energy recovery ventilation system that uses energy in exhaust air to precondition the temperature and moisture content of incoming fresh air. ConsERV™ typically saves energy, reduces CO2 emissions, and allows the overall HVAC system to be safely downsized. ConsERV™ introduces fresh ventilation air, resulting in higher productivity and sharper decision-making skills of building occupants, lowers triggers for allergies and asthma, and offers strong protection against key pathogens, including COVID-19 and most aggressive forms of bacteria.

Why is Dais on a rocket ship?

Nov. 29, 2021 Dais Corporation announced the Company has removed $2.12M of convertible, variable debt from its balance sheet.

3 Month Chart

5 Day Chart

Technical Analysis:

It is Bullish overall but this stock finished bearish and is up over 2,000%++. Be VERY careful and I wouldn’t look at this till it beats $6.20 or it will fall or best case consolidate. 

read more
Discussing Omicron, Facebook & SAND with Alexander Goldman

Discussing Omicron, Facebook & SAND with Alexander Goldman

Dec 2, 2021

A fireside introduction, without the fire, use your imagination!

I’m not a fortune teller, although I’ve been accused of it, I am a simple man that can read stock charts, read people and read a little of Spanlgish.  My name is Alexander Goldman but my friends call me Alex, let’s discuss the topics of the day.

Omicron, shall we drink?

Since the breakout variant Omicron has dominated the news, the Dow Jones Industrial Average has plummeted 2,000 points in two weeks. This market disturbance represents a 6% correction in just 10 trading days. 

Yesterday Moderna (MRNA) CEO Stephane Bancel told the Financial Times that the company’s current COVID-19 vaccine would likely see a “material drop” in effectiveness against Omicron, but that more data was still needed on the variant.

Let’s have a coffee, maybe with some Jameson Whiskey, & discuss, shall we?

The good news is, there are incredible opportunities in tragedies. Take a look above, remember the late/early spring of 2020? We rang in the New Year with grandiose visions of a Great Gatsby kinda 2020 and then boom, Covid! 

The market overreacted and share prices plummeted, then the market DOUBLED in 18 months. The truth is, I’m not drinking because of sorrow, I’m celebrating the opportunities on the horizon. 

Remember the song Gangster’s paradise by Coolio? Well, a trader’s paradise is volatility! Shorters went nuts in the winter of 2020 & the longs went bananas in the Spring. So, everyone come the fu@k down and double dip for god’s sake. Play the short and play the long and then go play some golf.

META, the social media giant formerly known as Facebook

Today Reuters writes, “Facebook risks missing the point of metaverse – and a coming shift in consumers’ behaviour – if it fails to permit digital ownership, according to some of the virtual world’s pioneers.

The social media giant (FB.O) made waves last month by changing its name to Meta Platforms and announcing a focus on the buzzy “metaverse”.

However, with few details beyond the rebrand, metaverse participants doubt it is ready to embrace the spirit driving creativity and profit in the space.

“What Facebook is doing with meta…is a ‘fake metaverse,’ unless they actually have a real description as to how we can truly own it,” said Yat Siu, chairman and co-founder of Animoca Brands, an investor in and builder of metaverse platforms, speaking on a panel at the Reuters Next conference.”

Haters are gonna hate & ainters are gonna aint, shall we discuss?

Is Yat Siu hating? Time will tell. On one hand, it’s Facebook and let’s face it, we might not like it, but they are profit geniuses. On the other hand, they became a juggernaut on the back of monetizing consumer data & being accused of centralizing political power, not decentralizing the power structure which the crypto/metaverse gang preaches. Can FB truly embrace decentralization in the name of profit, we will see. 

Don’t bring SAND to the beach, what about a META beach?

What is SAND.X? 

Truth be told, I didn’t know anything about SAND until I reached out to a trusted advisor about the MetaVerse and I asked, “If you were to invest in the meta verse? How and where?” He responds, “SAND”

I proceeded to research this stock called SAND and to my surprise, I couldn’t find it on the OTC, NASDAQ or Big Board! Do you know why? It’s a cryptocurrency and I got excited! Admit it, everyone who didn’t invest in Bitcoin a few years ago feels like they missed THE boat, and I feel the same way. So, SAND feels like a do over, another chance at Bitcoin. 

As my Ex Girlfriend used to say, We OOOOOO!

Is it too late?

Emma Newberry writes for Motley Fool and she alludes to it here, “there’s a lot of uncertainty about how the metaverse will develop and whether Sandbox can maintain that price.”

That is the 7 day chart ^ and it would appear that she is right, or is she?

Tune in next week to hear a stock trader’s opinion on the SAND chart, by the way I don’t know shit about crypto currencies!

read more
Winners and Losers: PTPI, MTTR, and NRXP

Winners and Losers: PTPI, MTTR, and NRXP

Nov 30, 2021

Company Name: Petros Pharmaceuticals, Inc.

Ticker: PTPI

Exchange: NASDAQ

Website: https://www.petrospharma.com/

Industry: Health & Wellness 

Company Summary:

Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men’s health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues including, but not limited to erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease, hormone health and substance use disorders.

Why is it so Bullish?

Nov. 30, 2021 Petros Pharmaceuticals announces that it has entered into definitive agreements with the company’s largest investor and other existing investors, for the purchase and sale of 3,333,333 shares of Petros Pharmaceuticals’ common stock, at a purchase price of $3.00 per share. The company will sell 2,153,333 shares in a registered direct offering and the remaining 1,180,000 shares will be sold in a private placement. Petros Pharmaceuticals has also agreed to issue the investors unregistered warrants to acquire 2,500,000 shares of common stock at an exercise price of $3.50 per share, exercisable immediately and terminating 5 years after the date of issuance. The closing of the offering is expected to occur on or about December 2, 2021, subject to the satisfaction of customary closing conditions.

1 Day Chart 

Technical Summary

Based on the 5 day chart and 1 day chart, I would consider this a bearish trend and would AGAIN, wait for confirmations of a reversal before considering a purchase. NOTE, the 1 month looks interesting but again the short term charts are bearish. 

—————————————————————————————————–

Company Name: Matterport, Inc. 

Ticker: (MTTR)

Exchange: NASDAQ

Website: https://matterport.com/

Industry: Tech  

Company Summary:

Matterport, Inc. (Nasdaq: MTTR) is leading the digital transformation of the built world. Our groundbreaking spatial data platform turns buildings into data to make nearly every space more valuable and accessible. Millions of buildings in more than 150 countries have been transformed into immersive Matterport digital twins to improve every part of the building lifecycle from planning, construction, and operations to documentation, appraisal and marketing.

Why is it so Bullish?

On Nov. 23, 2021 Matterport announced another expansion of Matterport Capture Services™ On-Demand that adds 16 U.S. cities and 20 in Great Britain to its service map, increasing its regional coverage by 55 percent.

5 Day Chart

Technical Summary

Love this stock, it is very bullish and has great news announced today, see below.

Nov. 30, 2021, Matterport introduced Matterport BIM file, a new add-on service that dramatically decreases the time and costs of Building Information Modeling (BIM) for the Architecture, Engineering, and Construction (AEC) industry. Now included with a Matterport subscription, customers can quickly transform a Matterport digital twin captured by a compatible 3D camera into a ready-to-use BIM file at the click of a button. The output is delivered in days, ready to be brought into their BIM application of choice. This new service significantly expedites projects and reduces associated costs by up to 70%, eliminating the traditional manual process that requires considerable time and effort.

—————————————————————————————————–

Company Name: NRx Pharmaceuticals, Inc. 

Ticker: (NRXP)

Exchange: NASDAQ

Website: www.nrxpharma.com 

Industry: Medical

Company Summary:

NRx Pharmaceuticals (NRx) draws upon more than 300 years of collective, scientific, and drug-development experience to bring improved health to patients. The Company is developing the BriLife® Covid vaccine, developed by the Israel Institute for Biological Research, under an exclusive license from the Israel Ministry of Defense. NRx is additionally developing ZYESAMI® (aviptadil) for patients with COVID-19, and has been granted Fast Track designation by the US Food and Drug Administration (FDA), and is currently undergoing phase 3 trials funded by the US National Institutes of Health, the Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Health and Human Services, and the Medical Countermeasures program, part of the US Department of Defense. The FDA has additionally granted Breakthrough Therapy Designation, a Special Protocol Agreement, and a Biomarker Letter of Support to NRx for NRX-101, an investigational medicine to treat suicidal bipolar depression. NRX-101 is currently in Phase 3 trials, with readouts expected in 2022.

Why is it so Bullish?

Nov. 29, 2021 NRx Pharmaceuticals announced today that it has completed an analysis to identify clinical evidence that indicates a substantial improvement after treatment with ZYESAMI® (aviptadil) in patients with Critical COVID-19 and Respiratory Failure over existing therapies such as remdesivir. NRx asked Prof. David Schoenfeld, one of the world’s most widely published statisticians with unique expertise in life-threatening diseases of the lung to conduct the analysis.

1 Day Chart 

Technical Summary:

Another Covid stock, another overbought play that could be a winner but we need confirmation and understanding that it will be volatile. 

read more